GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (WBO:GILD) » Definitions » Change In Other Working Capital

Gilead Sciences (WBO:GILD) Change In Other Working Capital : €-1,819 Mil (TTM As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Gilead Sciences Change In Other Working Capital?

Gilead Sciences's Change In Other Working Capital for the quarter that ended in Sep. 2024 was €100 Mil. It means Gilead Sciences's Other Working Capital increased by €100 Mil from Jun. 2024 to Sep. 2024 .

Gilead Sciences's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was €-1,621 Mil. It means Gilead Sciences's Other Working Capital declined by €1,621 Mil from Dec. 2022 to Dec. 2023 .

Gilead Sciences Change In Other Working Capital Historical Data

The historical data trend for Gilead Sciences's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Change In Other Working Capital Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -319.49 -343.62 -1,621.26

Gilead Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -825.50 -640.07 -191.36 -1,087.86 100.01

Gilead Sciences Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1,819 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (WBO:GILD) » Definitions » Change In Other Working Capital
Comparable Companies
BMY AMGN PFE BIIB OGN AMRN SCLX MIRA MRK ABBV LLY OCSE:NOVO B JNJ XSWX:ROG LSE:AZN XSWX:NOVN XPAR:SAN TSE:4519 LSE:GSK TSE:4568
Traded in Other Exchanges
GILD:USA GILD:Peru GILD:Mexico 1GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD:Chile GILD34:Brazil GILD:Argentina
Address
333 Lakeside Drive, Foster, CA, USA, 94404
Website
https://www.gilead.com
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).